NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=128320&wire=1 or contact Joseph E. Levi, Esq.

KORU Medical Systems' stock has surged 60% since November, driven by the success of its FREEDOM System for subcutaneous immunoglobulin delivery. The SCIg market is growing rapidly, with KORU outperforming competitors by capturing market share and benefiting from trends like prefilled syringes. Strong international growth, new therapies, and product innovations are key drivers, with significant revenue from recurring patients and promising future launches.

Kenvue's stock has underperformed since its IPO, with disappointing guidance cuts for 2023 and 2024, and minimal growth projected for 2025. Despite recent struggles, Kenvue's strong brand portfolio, including Tylenol and Band-Aid, suggests potential for a turnaround, supported by activist investor Starboard Value. Execution issues, external factors, and potential structural changes have impacted Kenvue's performance, but improvements in marketing and management could drive future growth.

McDonald's is expected to report another quarter of same-store sales declines. Traffic to the fast-food giant's U.S. restaurants fell after the Centers for Disease Control and Prevention linked its Quarter Pounder burgers to an E.

97% of CEOs plan AI integration, but only 1.7% feel fully prepared. New research highlights what's getting in the way of progress – and how CEOs plan to shift ambition into action.

Investors are shifting towards value stocks, benefiting sectors like Financials, Health Care, and Materials, which supports a buy rating on SPGP. Invesco S&P 500 GARP ETF focuses on 'growth at a reasonable price,' offering a balanced approach between high-growth stocks and value stocks, with a favorable PEG ratio of 1.5. Despite volatility, SPGP has returned 6% this year, with a strong seasonal trend expected from February to July and a positive technical outlook.

While being the most expensive SaaS business in the market, there's a plausible narrative that Palantir may be fairly valued at a mere 30% revenue CAGR. Q4 2024 results give confidence to prior concerns of lacking customer count growth, which is a core driver of the scalability of the business. The launch and proper monetization of Palantir's AIP product, along with its bootcamp strategy, have driven accelerated revenue growth and customer scalability.

Carole Madjo, head of European luxury goods research at Barclays, weighs in on the outlook for the luxury sector as firms look for ways to respond to weaker consumer demand.

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form-2?prid=128319&wire=1 or contact Joseph E. Levi, Esq.

The Ivy Portfolio allocates 20% each to domestic stocks, international stocks, intermediate bonds, commodities, and REITs, mimicking Harvard and Yale endowments. REITs offer high returns, low correlation with stocks, and psychological benefits, but they crash with markets and are tax inefficient. Most people already have significant real estate exposure, making additional REIT investments risky; a small allocation in a diversified portfolio is ideal.

Despite PayPal's Q4 2024 earnings beating expectations, the stock dropped by 13% due to a slowdown in unbranded checkout growth and a decline in the number of transactions. Despite the market overreaction, PYPL's underlying fundamentals remain intact. PayPal is still a competitively strong and profitable business with a strong balance sheet. The Company's focus on small and medium-sized businesses promises higher margins, which could offset the slowdown in its TPV with a higher transaction margin.

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your TELUS International (Cda) Inc. (NYSE:TIXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/telus-international-lawsuit-submission-form?prid=128318&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Integral Ad Science Holding Corp. (NASDAQ:IAS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/integral-ad-science-lawsuit-submission-form?prid=128317&wire=1 or contact Joseph E. Levi, Esq.

Verizon, part of Rose's Income Garden Portfolio, offers a 6.75% yield, making it a strong income stock with reliable dividends and fair valuation. Verizon's extensive fiber network and recent acquisitions position it well for future growth, despite lagging in 5G and facing potential debt issues. The company has a solid dividend history, paying rising dividends for 20 years, with a current payout ratio of 58.22% and a BBB+ credit rating.

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Transocean Ltd. (NYSE:RIG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transocean-ltd-lawsuit-submission-form?prid=128316&wire=1 or contact Joseph E.

The Invesco Dorsey Wright SmallCap Momentum ETF has a strong growth profile but has underperformed other small-cap momentum funds like XSMO and USVM since 2021. DWAS focuses on U.S. small-cap companies with strong relative performance, heavily weighted towards industrials and technology sectors, and has a high turnover rate. Despite outperforming the Russell 2000 index over time, DWAS has higher volatility, lower liquidity, and higher expense ratios compared to peer funds.

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=128315&wire=1 or contact Joseph E. Levi, Esq.

RADNOR, Pa. , Feb. 9, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Crocs, Inc. (NASDAQ: CROX) ("Crocs" or the "Company") on behalf of investors who purchased or otherwise acquired Crocs common stock between November 3, 2022, and October, 28 2024, inclusive (the "Class Period").

Philip Morris delivered strong Q4 results, surpassing EPS and revenue estimates, driven by surging demand for non-traditional products like IQOS and ZYN. Non-traditional products now represent 40% of total revenue, significantly boosting gross profits. Despite strong performance and profitability, I maintain a hold rating due to Philip Morris' high valuation with a forward P/E ratio of 18.7X.

LendingClub's stock fell 20% post-earnings due to mixed results and guidance, presenting a buying opportunity for long-term investors. Despite concerns over loan origination growth, LC focuses on high credit quality and prudent growth, aiming for >$2.3 billion in 2025. Valuation remains low, and if 2025 guidance is conservative, the stock could see significant upside, currently trading at ~1.2x book value.